The role of serum uric acid (SUA) in the context of adverse cardiovascular events in hypertensive subjects is controversial. Additionally, the relationship between SUA and indices of target organ damage is not well defined in this setting. Towards this end, we studied 842 consecutive nondiabetic patients with stage I-II essential hypertension (office blood pressure ¼ 148/95 mmHg, aged 53.4 years), referred to our outpatient hypertensive unit within a period of 4 years. According to the urinary albumin excretion (UAE), the study population was classified into those with microalbuminuria [MA( þ ), UAE ¼ 20-200 mg/24 h, n ¼ 222] and those without MA [MA (À), UAEo 20 mg/24 h, n ¼ 620]. Moreover, according to the presence of left ventricular hypertrophy (LVH) the participants were subdivided into two additional groups: [LVH ( þ ), n ¼ 305 and LVH (À), n ¼ 537]. SUA levels were higher by 0.4 mg/dl, (P ¼ 0.04) in group MA ( þ ) compared with the group MA (À), while no difference was observed between groups LVH ( þ ) and LVH (À) (P ¼ NS). In the entire population, SUA was correlated with body mass index (BMI) (r ¼ 0.17, Po0.001), waist/hip ratio (r ¼ 0.3, Po0.001), office systolic blood pressure (SBP) (r ¼ 0.14, Po0.05), triglycerides levels (r ¼ 0.25, Po0.001), UAE (r ¼ 0.35, Po0.001) and HDL (r ¼ À0.26, Po0.001). Multiple regression analysis demonstrated that SUA was significantly related with BMI, office SBP and UAE (Po0.05). In conclusion, increased SUA levels are associated with MA but not with LVH in essential hypertensive subjects. Whether these inter-relationships may elucidate the clinical positioning of augmented SUA in this setting remains to be clarified in future studies.
Introduction
Despite the numerous studies conducted over the past 50 years, controversy still exists regarding the possible relationship between serum uric acid (SUA) and cardiovascular complications. The recent guidelines of the European Society of Hypertension-European Society of Cardiology 1 suggest the routine laboratory measurement of SUA levels in all hypertensive subjects, but the role of these latter regarding the cardiovascular risk stratification of such patients remains unclear. Several studies have defined a positive correlation between SUA and cardiovascular complications, in both the general population, [2] [3] [4] [5] and in essential hypertensive patients. [6] [7] [8] However, in some cohorts, this positive association became vague or did not remain statistically significant after multivariate adjustments for classic risk factors, 9, 10 while in others it still remained significant and unaffected.
Arterial hypertension, accompanied by hyperuricaemia in about 25% of cases, 11 and SUA may directly affect cardiovascular risk through several mechanisms. 12, 13 Interestingly, it has been found that microalbuminuria (MA), an established index of target organ damage, frequently coexists with elevated SUA levels in hypertensive patients with the metabolic syndrome.
14 Moreover, in hypertensive patients with left ventricular hypertrophy (LVH), lower SUA levels were associated with a better prognosis. 15 As a result of the existing debate regarding the impact of SUA on cardiovascular morbidity and mortality, we sought to determine whether there is any correlation between SUA levels and subclinical target organ derangement such as increased values of urinary albumin excretion (UAE) and left ventricular (LV) mass index, in middle-aged, nondiabetic essential hypertensive patients.
Materials and methods

Study population
We studied 2197 consecutive patients, (aged 54.9 years), with stage I-II essential hypertension (office BP ¼ 147/92 mmHg), referred to the outpatient hypertensive unit of our institution, within a period of 4 years (from 1999 to 2002). The presence and severity of hypertension were determined on the basis of office BP measurements, according to JNC VI guidelines. 16 All subjects underwent the usual clinical and laboratory work-up in order to rule out secondary hypertension.
Patients with renal failure, overt proteinuria, diabetes mellitus or impaired glucose tolerance, history of coronary artery disease, stroke, intermittent claudication, significant valvular heart disease, familial hypercholesterolaemia, chronic obstructive pulmonary disease, or any other significant concurrent systemic illness were excluded from the study. Moreover, women taking oral contraceptives or oestrogen replacement therapy were also excluded. In all, 1318 patients who fulfilled the above criteria were finally selected for participation in the study. The study protocol included anthropometric and metabolic determinations, as well as echocardiographic examination. Since complete data regarding the aforementioned parameters were obtained in 842 out of the 1318 patients, the former constituted our final study population. Some of the included patients were newly diagnosed and never treated with antihypertensive drugs (n ¼ 295, 35%) while the others who were on therapy (n ¼ 547, 65%), entered the study after a period of at least 4 weeks washout. In addition, the subjects who were receiving xanthine oxidase inhibitors (n ¼ 41, 4.8%), also underwent washout before entering the study.
Anthropometric determinations
Weight and height were measured by standard techniques, and body mass index (BMI) was calculated as body weight in kilograms divided by height in metres squared. Waist circumference was measured at the midpoint between the lower rib margin and the iliac crest, and hip circumference was measured at the trochanter level. Both circumferences were measured to the nearest 0.5 cm with a plastic tape and the ratio between them provided the waist/hip ratio.
Cardiac ultrasonography
Echocardiographic studies were performed by an experienced senior cardiosonographer using an ATL-4 ultrasound imager equipped with a 2.5-5 MHz transducer, according to the guidelines of the American Society of Echocardiography. 17, 18 The echocardiographic estimations included the standard 2D and M-mode measurements, such as septal wall thickness, LV posterior wall thickness, and LV end systolic and end diastolic diameter. LV mass was measured by using the Penn convention, and LV mass index was calculated as LV mass divided by body surface area. Moreover, relative wall thickness was calculated using the following formula: (septal wall thickness þ LV posterior wall thickness)/(LV end diastolic diameter).
Metabolic determinations
Blood sampling by a peripheral vein was performed in all subjects between 7:30 and 9:30 am after a 12-h fast, in order to determine lipidaemic profile, SUA, glucose and creatinine levels. Additionally, all patients were asked to collect a single 24-h urine sample from 0800 to 0800, in order to determine the UAE. Urinary albumin concentrations were measured by an immunonephelometric technique with a limit of detection of 0.4 mg/dl and an interassay variation of 0.035. Microalbuminuria (MA) was defined as UAE values between 20 and 200 mg/ 24 h, 19 while UAE values o20 mg/24 h were considered as normal.
Statistical analysis
Data are expressed as mean7standard deviation (s.d.). Significant differences between the different groups were determined using the Student's independent sample t-test, or the w 2 test where appropriate. Spearman's correlation was performed in order to determine correlations between any of the parameters. Multiple linear regression analysis was used to evaluate the relations of demographic, clinical, echocardiographic and laboratory parameters with UAE and LV mass index. All tests were considered to be significant at the level of Po0.05.
Results
For the pooled study population (48.3% males, mean age 53.4 years, office BP ¼ 148/95 mmHg), BMI was 28.60 kg/m 2 , waist/hip ratio was 0.89, and mean duration of hypertension was 5.5 years. Moreover, 31.1% of the participants were smokers, while regarding the biochemical parameters, serum glucose was 99 mg/dl, serum creatinine was 0.94 mg/dl, total cholesterol was 224 mg/dl, LDL cholesterol was 146 mg/dl, HDL cholesterol was 50 mg/dl, triglycerides were 125 mg/dl, and SUA was 4.88 mg/dl.
Firstly, according to the UAE values, the study population (n ¼ 842) was divided into those without MA [MA (À), n ¼ 620, UAEo20 mg/24 h], and those
The two subgroups did not differ regarding age, sex, BMI, smoking status, duration of hypertension, heart rate, office SBP and office pulse pressure (PP) ( Table 1) . Furthermore, microalbuminurics compared with normoalbuminurics had significantly augmented waist/hip ratio (by 0.02, P ¼ 0.03) and office DBP (by 3 mmHg, P ¼ 0.02). The two subgroups did not differ regarding serum glucose, serum creatinine, total cholesterol, HDL cholesterol, LDL cholesterol and triglyceride concentrations. Only SUA levels were significantly higher in group MA ( þ ) compared with group MA (À) (by 0.4 mg/dl, P ¼ 0.04).
Regarding the echocardiographic data, in the entire study population, LV mass index was within the normal values and group MA ( þ ) compared with group MA (À) had a greater LV mass index (by 6 g/m 2 ), but this difference did not reach statistical significance (P ¼ NS). Additionally, the two groups did not differ regarding the relative wall thickness. Based on the gender-specific criteria for LVH (LV mass index 4116 g/m 2 for males and 4104 g/m 2 for females), our study population was divided into those with LVH [LVH ( þ ), n ¼ 305] and those without LVH [LVH (À), n ¼ 537]. The two groups did not differ regarding sex, BMI, waist/hip ratio and smoking status (Table 2 ). However, patients of LVH ( þ ) group compared with those of LVH (À) group were older (by 9 years, P ¼ 0.001), and presented significantly greater values of office SBP (by 7 mmHg; Po0.05), as well as office PP by 8 mmHg (Po0.05). Furthermore, no statistically significant difference was observed regarding biochemical parameters although a trend for higher values of UAE was noted in LVH ( þ ) group.
In the total population, LV mass index was significantly correlated with age (r ¼ 0.32, Po0.001), BMI (r ¼ 0.11, Po0.05), waist/hip ratio (r ¼ 0.17, Po0.001), office SBP (r ¼ 0.23, Po0.001) and UAE (r ¼ 0.27, Po0.05). In addition, UAE was positively related with office SBP, DBP and waist/ hip ratio (r ¼ 0.12, 0.14 and 0.26, respectively, Po0.01 for all cases). Moreover, the significant correlations of SUA with demographic and laboratory parameters are presented in Table 3 .
By a multiple linear regression model, it was revealed that UAE levels were significantly correlated with BMI, LV mass index, office SBP and SUA values (Table 4a) . Furthermore, by another multiple linear regression model, it was demonstrated that LV mass index was significantly associated with age, sex, BMI, office SBP and UAE, but not with SUA (Table 4b ).
Discussion
The main finding of our study was that SUA concentrations in essential hypertensive patients are accompanied by augmented UAE, but not by increased LV mass index. Moreover, SUA levels were correlated with a clustering of well-known cardiovascular risk factors, such as increased body weight, dyslipidaemia and higher levels of office SBP.
The finding that microalbuminuric subjects exhibited higher levels of SUA could be attributed to several pathophysiological mechanisms. First, it has been shown that elevated SUA levels usually coexist with other risk factors that predispose to renal damage. This possibly means that SUA promotes renal dysfunction, at least, as a cofactor, but not necessarily in an independent manner. Another Uric acid and target organ damage C Tsioufis et al possible explanation could be their mutual correlation with hyperinsulinaemia. It is well-known that hyperinsulinaemia results in reduced renal clearance of urate (ie the soluble form of uric acid in blood) and furthermore stimulates sodium and urate reabsorption in the renal proximal tubule. 20 Moreover, in a pioneer study, 21 it was revealed that hyperinsulinaemia strongly correlates with MA, a finding that was further established by other investigators. [22] [23] [24] Consequently, it could be suggested that the hyperinsulinaemic state represents an intermediate link between elevated SUA concentrations and early renal involvement, reflected by augmented UAE. Finally, endothelial dysfunction seems to play a pivotal role regarding the relationship between SUA levels and increased UAE in this setting. It is well known that hypertension causes alterations in the structural and functional properties of the microvasculature. One of the major adverse effects of the above-mentioned phenomena is local tissue ischaemia, which leads to increased uric acid production both via inhibition of urate secretion, and via increased uric acid synthesis due to enhanced xanthine oxidoreductase gene expression. 25 Apart from the augmented uric acid production, concomitant superoxide formation also takes place, while it has been proposed that xanthine oxidoreductase may directly cause endothelial dysfunction, 13 although the exact mechanism is not yet well determined. 
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Currently, there are cumulative data supporting that proinflammatory mechanisms are involved both in the pathogenesis and cardiovascular complications of essential hypertension. 26 Accordingly, several investigators reported an intriguing association between UAE and several inflammatory mediators in various clinical settings including hypertensive populations. Based on the aforementioned, one could hypothesize that the inter-relationship between SUA and UAE may be at least partially attributed to their common link with the proinflammatory state, although this hypothesis remains highly speculative. In consistence with the previous data, it has been reported that uric acid stimulates smooth muscle cell proliferation and exerts proinflammatory actions. 27 Moreover, hyperuricaemia may lead to impaired oxidative metabolism and enhanced platelet adhesiveness and aggregation, 12 which represent different aspects of endothelial dysfunction. Taking into consideration that MA is an integrated marker of systemic endothelial dysfunction 28 beyond the renal glomerulus, it could be suggested that the underlying cause of augmented UAE, at least partially, is the consequence of uric acid-induced endothelial dysfunction, in this setting.
A large body of evidence supports that MA is associated with a higher risk of cardiovascular complications and adverse outcomes in essential hypertensive patients. [29] [30] [31] [32] [33] [34] In contrast, the independent cardiovascular prognostic role of SUA is still debatable since in the majority of studies it is suggested that it might be the result of complex interactions with other well-defined risk markers. In line with the previous data, Alderman et al 35 found that SUA levels were positively associated with future cardiovascular adverse events in patients with essential hypertension, although this association was not statistically significant in both the white population and in subjects without a history of previous cardiovascular disease. Similarly, in the European Working Party on High Blood Pressure in the Elderly trial, 36 a significant univariate association between pretreatment SUA concentrations and cardiac mortality disappeared after adjustment for age, gender and previous cardiac disease, while in the SHEP Study, 37 SUA was a univariate predictor of coronary events, but its predictive role weakened after multivariate adjustments. Moreover, in an update from the Framingham Heart Study, 10 although SUA levels were positively associated with the risk of adverse cardiovascular events and mortality in women, this association lost statistical significance after multivariate adjustment for additional factors, such as arterial hypertension, age, total cholesterol levels and use of diuretics. In agreement with previous studies, we found that SUA levels were correlated with increased body weight and dyslipidaemia. However, it is not yet known if SUA acts synergistically with the other risk factors or independently (ie by applying direct toxic effects in the vascular bed), and further studies are probably needed in order to clarify the exact mechanisms. In other words, we could suggest that SUA may provide additional prognostic information in patients with essential hypertension, especially when it is combined with other established risk factors like increased UAE.
Despite the established associations of increased UAE with LV mass index and the described correlation in our study between UAE and SUA levels, the latter were not found to be correlated with LVH. Such an association would not be expected from a pathophysiological point of view, although it cannot be considered impossible, since LVH represents a complex entity in the aetiology of which many mechanisms are involved, including the activation of neurohumoral systems. However, the findings of the recent LIFE Study 15 in hypertensive patients with LVH indicate that a treatmentinduced concomitant decrease in SUA concentrations along with the regression of LVH may also contribute to the total cardiovascular risk reduction in this setting.
Serum uric acid levels in essential hypertensive subjects and target organ damage.
What is known
Increased SUA levels are accompanied by a clustering of known cardiovascular risk factors, such as increased BMI, dyslipidaemia and increased levels of BP; In essential hypertensives with LVH, lower SUA levels are associated with better prognosis; Increased SUA levels are related with increased cardiovascular risk, probably via interactions with other established risk factors (see above).
What this study adds
Increased SUA levels are indeed accompanied by established cardiovascular risk factors; No correlation between SUA and LVH; The direct association between SUA and UAE provides a possible mechanism linking augmented SUA levels with adverse cardiovascular prognosis in essential hypertensives.
Potential limitations of our study may not permit the global application of our findings. First, only a single 24-h urine sample was used for the assessment of UAE, instead of consecutive collections that would have been preferable. Second, due to the strict inclusion criteria we had applied, as well as the absence of complete data in some patients, the number of subjects who finally constituted our study group is rather a selective one. Third, despite the washout period of 4 weeks, we cannot exclude the possibility that the previous treatment with antihypertensive drugs as well as with xanthine oxidase inhibitors could have influenced, at least partially, the results of the study. Fourth, the number of the study participants was not large enough, and therefore we did not perform a further group analysis, regarding the possible inter-relationships of microalbuminuria with LV mass, in this setting.
In conclusion, our finding that a significant relationship exists between SUA and UAE, supports the concept that SUA levels should be considered as an important factor in the evaluation of the total cardiovascular risk in essential hypertensive patients. This may be crucial regarding the treatment decisions in the setting of essential hypertension, and future studies are required in order to elucidate whether lifestyle and/or pharmaceutical reduction of SUA levels could improve the prognosis of such patients.
